Video

Dr. Wong on treatment sequence in metastatic urothelial carcinoma

Author(s):

Urology Times staff

Risa Wong, MD, discusses the sequencing of treatments in the metastatic urothelial carcinoma armamentarium, including chemotherapy, immune checkpoint inhibitors, and antibody-drug conjugates. Wong is a hematology/oncology fellow at the University of Washington and Fred Hutchinson Cancer Research Center in Seattle.

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Related Content
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
May 12th 2025

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

Hannah Clarke
The phase 3 RC48-C016 trial met its primary end points.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Physical function and frailty measures offer distinct insights in patients with bladder cancer
May 7th 2025

Physical function and frailty measures offer distinct insights in patients with bladder cancer

Hannah Clarke
Data showed that physical function and self-reported frailty assessments were poorly correlated.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
May 5th 2025

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

Hannah Clarke
The sBLA for NAI was submitted to the FDA in March 2025.
FDA updates in urology: April 2025
May 1st 2025

FDA updates in urology: April 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from April 2025.
© 2025 MJH Life Sciences

All rights reserved.